Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.65 |
| ▸ | FAAH | O00519 | 4/20 | 0.62 |
| ▸ | NAAA | Q02083 | 1/20 | 0.61 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.59 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18796591 | 1.00 | CASP2 (0.65) | CASP2FAAHNAAASLC6A5DNM1 | |
| SCHEMBL2915044 | 1.00 | CASP2 (0.65) | CASP2FAAHNAAASLC6A5DNM1 | |
| SCHEMBL6139361 | 1.00 | CASP2 (0.65) | CASP2FAAHNAAASLC6A5DNM1 | |
| SCHEMBL6705635 | 1.00 | CASP2 (0.65) | CASP2FAAHNAAASLC6A5DNM1 | |
| SCHEMBL6139231 | 1.00 | CASP2 (0.65) | CASP2FAAHNAAASLC6A5DNM1 | |
| SCHEMBL24087524 | 1.00 | CASP2 (0.65) | CASP2FAAHNAAASLC6A5DNM1 | |
| SCHEMBL20542925 | 1.00 | CASP2 (0.65) | CASP2FAAHNAAASLC6A5DNM1 | |
| SCHEMBL20543068 | 1.00 | CASP2 (0.65) | CASP2FAAHNAAASLC6A5DNM1 | |
| SCHEMBL21842282 | 1.00 | CASP2 (0.65) | CASP2FAAHNAAASLC6A5DNM1 | |
| SCHEMBL27112954 | 1.00 | CASP2 (0.65) | CASP2FAAHNAAASLC6A5DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210378980-A1 | PREPARATION OF LIPID NANOPARTICLES AND METHODS OF ADMINISTRATION THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2021-12-09 | — | — | US | disclosed |
| WO-2020061457-A1 | PREPARATION OF LIPID NANOPARTICLES AND METHODS OF ADMINISTRATION THEREOF | MODERNATX, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| EP-3368508-A1 | IMMUNOSTIMULATING AGENT | AJINOMOTO CO., INC. (JP) | 2018-09-05 | — | — | EP | disclosed |
| WO-2017073797-A1 | IMMUNOSTIMULATING AGENT | AJINOMOTO CO., INC. (JP) | 2017-05-04 | — | — | WO | disclosed |
| US-20040092599-A1 | Production process of guanidine derivative containing amido group and salt thereof | AJINOMOTO CO., INC. (JP) | 2004-05-13 | — | — | US | disclosed |
| EP-1270552-A2 | Production process for a guanidine derivative containing an amido group and for a salt thereof | Ajinomoto Co., Inc. (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210378980-A1 | PREPARATION OF LIPID NANOPARTICLES AND METHODS OF ADMINISTRATION THEREOF | LIPA, PLTP, CETP | CASP2 2193/4885FAAH 1067/4885NAAA 860/4885 |
| US-20040092599-A1 | Production process of guanidine derivative containing amido group and salt thereof | FASN, GMPS, CEL | CASP2 1562/4885FAAH 278/4885NAAA 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.